Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

IOPROMIDE FOR SYSTEM SUITABILITY 1 CRS (5 MG)

IOPROMIDE FOR SYSTEM SUITABILITY 1 CRS (5 MG)

73334-07-3

DISCOVER
IOPROMIDE FOR SYSTEM SUITABILITY 2 CRS (5 MG)

IOPROMIDE FOR SYSTEM SUITABILITY 2 CRS (5 MG)

73334-07-3

DISCOVER
NICOTINE FOR SYSTEM SUITABILITY CRS (1 MG)

NICOTINE FOR SYSTEM SUITABILITY CRS (1 MG)

03/06/6019

DISCOVER
ASCORBIC ACID IMPURITY C CRS (30 MG)

ASCORBIC ACID IMPURITY C CRS (30 MG)

342385-52-8

DISCOVER
BENAZEPRIL HYDROCHLORIDE CRS (170 MG)

BENAZEPRIL HYDROCHLORIDE CRS (170 MG)

86541-74-4

DISCOVER
BENAZEPRIL IMPURITY A CRS (20MG)

BENAZEPRIL IMPURITY A CRS (20MG)

NA

DISCOVER
BETAMETHASONE VALERATE FOR SYSTEM SUITABILITY CRS (20 MG)

BETAMETHASONE VALERATE FOR SYSTEM SUITABILITY CRS (20 MG)

2152-44-5

DISCOVER
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE CRS (5 MG)

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE CRS (5 MG)

217087-09-7

DISCOVER
GINSENG DRY EXTRACT HRS (500 MG)

GINSENG DRY EXTRACT HRS (500 MG)

NA

DISCOVER
LAMOTRIGINE CRS (15 MG)

LAMOTRIGINE CRS (15 MG)

84057-84-1

DISCOVER
LAMOTRIGINE FOR PEAK IDENTIFICATION CRS (15 MG)

LAMOTRIGINE FOR PEAK IDENTIFICATION CRS (15 MG)

84057-84-1

DISCOVER
LAMOTRIGINE IMPURITY E CRS (15 MG)

LAMOTRIGINE IMPURITY E CRS (15 MG)

50-45-3

DISCOVER